EMA drug communication reviewed

The European Medicines Agency's (EMA) communication strategy concerning the benefits and risks of medicines has been put under the spotlight by an independent report.

The report represents the outcome of a year-long project carried out by Dr Frederic Bouder, from Maatstricht University, on the invitation of the agency.

Dr Bouder carried out a detailed analysis of the expectations and attitudes of the agency's stakeholders towards its communication on medicines.

He recommended that the agency set up a risk communication advisory board, form a strategic view on transparency, involve patients in communication activities on a routine basis, and review the format and timing of its communication vehicles.

The EMA has started implementing some of Dr Bouder's suggestions. It is also considering his recommendations during the implementation of the new pharmacovigilance legislation.

The EMA has the report available to download (PDF).